Journal article
Real-world evaluation of the DESMOND type 2 diabetes education and self-management programme
S Chatterjee, MJ Davies, B Stribling, A Farooqi, K Khunti
Practical Diabetes | JOHN WILEY & SONS LTD | Published : 2018
DOI: 10.1002/pdi.2154
Abstract
Diabetes education and self-management programmes are associated with improved biomedical, psychosocial and behavioural outcomes according to a number of randomised controlled trials (RCT) and systematic reviews. Observational studies are necessary to determine whether delivery of this education translates to improved outcomes in the real world. In 2008, the results of an RCT evaluating Diabetes Education and Self-Management for Ongoing and Newly Diagnosed (DESMOND) in a multi-ethnic population were published confirming the benefits of participating in this programme with sustained improvements at three years along with confirmed cost-effectiveness. DESMOND has therefore been recommended by ..
View full abstractGrants
Funding Acknowledgements
Dr Chatterjee has received speaker fees, educational funding or both from Janssen, Eli Lilly, Novo Nordisk, AstraZeneca, and Boehringer Ingelheim, and grants in support of investigator-initiated trials from Boehringer Ingelheim, and Janssen.Prof Davies reports personal fees from: Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Janssen, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals International Inc; also grants from: Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, and Janssen.Prof Khunti has acted as a consultant and speaker for AstraZeneca, Novartis, Novo Nordisk, SanofiAventis, Lilly, Merck Sharp & Dohme, Janssen, and Boehringer Ingelheim. Prof KK has received grants in support of investigator and investigator-initiated trials from Astra Zeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, Merck Sharp & Dohme, and Roche. Prof KK has served on advisory boards for AstraZeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Janssen, and Boehringer Ingelheim.